---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-057782"
form_type: "8-K"
ticker: "NVCT"
cik: "0001875558"
company_name: "Nuvectis Pharma, Inc."
filed_at: "2024-05-07T23:59:59+00:00"
generated_at: "2026-06-02T20:43:59.606417+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Nuvectis Q1 2024 net loss $4.2M; cash $19.5M; NXP800 Phase 1b data encouraging

## Summary
- Net loss $4.2M in Q1 2024 vs $4.0M in Q1 2023; cash $19.5M (up from $19.1M in Dec 2023).
- NXP800 Phase 1b in platinum-resistant ARID1a-mutated ovarian cancer shows encouraging preliminary data; FDA Fast Track granted.
- NXP900 preclinical data at AACR: robust activity in NSCLC cell lines; synergy with alectinib and osimertinib.
- R&D expense $2.7M (+$0.3M YoY); G&A $1.7M flat; interest income $0.2M (vs $0.1M).
- Several clinical data updates expected in 2H 2024; cash runway estimated into 2H 2025.

## SEC filing metadata
- accession: 0001104659-24-057782
- form_type: 8-K
- ticker: NVCT
- cik: 0001875558
- company_name: Nuvectis Pharma, Inc.
- filed_at: 2024-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1875558/000110465924057782/0001104659-24-057782-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1875558/000110465924057782/tm2413597d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-057782
- JSON: https://secwatch.observer/filing/0001104659-24-057782.json
- Plain text: https://secwatch.observer/filing/0001104659-24-057782.txt

## Key facts
- Earnings Releases
  Nuvectis Pharma, Inc. reported first quarter ended March 31, 2024 results: net income $4.2 million.
  - Period: first quarter ended March 31, 2024
  - Net income: $4.2 million
  - Result: reported results
  source text: First Quarter 2024 Financial Results Cash, and cash equivalents were $19.5 million as of March 31, 2024, compared to $19.1 million as of December 31, 2023. The increase of $0.4 million in the cash balance in the first quarter of 2024 is a result of the utilization of the at-the-market facility, partially offset by the operating expenses for the quarter. The Company's net loss was $4.2 million for the three months ended March 31, 2024, compared to $4.0 million for the three months ended March 31, 2023, an increase in net loss of $0.2 million.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1875558/000110465924057782/0001104659-24-057782-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.